TENX vs. TRVN, CMMB, GRAY, EFTR, CANF, IBIO, UPC, SBFM, ENVB, and KTTA
Should you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Trevena (TRVN), Chemomab Therapeutics (CMMB), Graybug Vision (GRAY), eFFECTOR Therapeutics (EFTR), Can-Fite BioPharma (CANF), iBio (IBIO), Universe Pharmaceuticals (UPC), Sunshine Biopharma (SBFM), Enveric Biosciences (ENVB), and Pasithea Therapeutics (KTTA). These companies are all part of the "pharmaceutical preparations" industry.
Tenax Therapeutics (NASDAQ:TENX) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.
Trevena received 475 more outperform votes than Tenax Therapeutics when rated by MarketBeat users. Likewise, 72.18% of users gave Trevena an outperform vote while only 58.58% of users gave Tenax Therapeutics an outperform vote.
Tenax Therapeutics has higher earnings, but lower revenue than Trevena.
Tenax Therapeutics' return on equity of -65.79% beat Trevena's return on equity.
Tenax Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Comparatively, Trevena has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
Tenax Therapeutics presently has a consensus price target of $480.00, suggesting a potential upside of 13,693.10%. Trevena has a consensus price target of $9.00, suggesting a potential upside of 2,201.79%. Given Tenax Therapeutics' higher probable upside, equities analysts clearly believe Tenax Therapeutics is more favorable than Trevena.
1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 1.9% of Tenax Therapeutics shares are held by insiders. Comparatively, 2.4% of Trevena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Trevena had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 3 mentions for Trevena and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.00 beat Trevena's score of 0.67 indicating that Tenax Therapeutics is being referred to more favorably in the media.
Summary
Tenax Therapeutics and Trevena tied by winning 6 of the 12 factors compared between the two stocks.
Get Tenax Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tenax Therapeutics Competitors List
Related Companies and Tools
